{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.6","upperLimit":"59.6","value":"45.3"},{"groupId":"OG001","lowerLimit":"3.7","upperLimit":"30.4","value":"13.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"The ORR was assessed by independent central review utilizing the International Working Group \\[IWG\\] response assessment criteria per Cheson 2007 of pembrolizumab in participants with rrPMBCL. For participants with rrRS, IWG criteria with special considerations for RS was used for progression. The ORR was defined as the percentage of participants who had a response (complete response, CR or partial response, PR) prior to disease progression. CR is the disappearance of all evidence of disease and PR is the regression of measurable disease and no new sites. Participants with missing data were considered non-responders. In the rrPMBCL cohort, an exact binomial test was conducted versus a fixed historical control rate. For the rrPMBCL cohort, the ORR was estimated as well as a 95% 2-sided exact confidence interval (CI) using the Clopper-Pearson method whereas the rrRS cohort was estimated with a 90% 2-sided CI.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pembrolizumab 200 mg every 3 weeks (Q3W), intravenous infusion (IV) on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).","id":"OG000","title":"Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)"},{"description":"Pembrolizumab 200 mg Q3W, IV on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).","id":"OG001","title":"Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS)"}],"paramType":"NUMBER","populationDescription":"The analysis population included all participants who received at least one dose of study medication (pembrolizumab).","reportingStatus":"POSTED","timeFrame":"Up to approximately 27 months (Database Cutoff: 28MAY2019)","title":"Objective Response Rate (ORR) Based on International Working Group (IWG) Response Assessment Criteria Per Independent Central Review","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}